Novel compounds as LRRK2 protein kinase domain inhibitors

Abstract

The present invention relates to a pharmaceutical composition comprising a novel LRRK2 protein kinase domain inhibitor or a pharmaceutically acceptable salt thereof for preventing or treating diseases mediated by or associated with LRRK2, and a method for treating and preventing diseases using same.

Description

Description of Invention

Title of invention

Technical Field

Background Art

Summary of Invention

Technical Problem

Technical Solution

Advantageous Effects of Invention

Brief Description of Drawings

Best Mode for Carrying Out the Invention

Claims

Claim 1. A compound of Formula 1 below, or a pharmaceutically acceptable salt thereof:[Formula 1]wherein, is each independently absent or a single bond,X1 to X4 are each independently C or N,R1 and R2 are each independently hydrogen, alkyl, -O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl, or -alkyl-heteroaryl, or R1 and R2 are heterocycloalkyl formed by linking R1 and R2 together,R3 is absent, or is hydrogen, halo, cyano, alkyl, -alkyl-O-alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl,R4 is hydrogen, halo, cyano, -NH2, -alkyl, -alkyl-O-alkyl, -O-alkyl, N(R4A)(R4B), -N(R4D)C(=O)(R4C), cycloalkyl, heterocycloalkyl, aryl, or heteroaryl,wherein R4A to R4D are each independently hydrogen, alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-heteroaryl, heteroaryl, aryl, or -aryl-C(=O)-heterocycloalkyl,R5 is hydrogen, cyano, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl,R6 is absent, or is hydrogen, cyano, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl,wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted with one or more selected from the group consisting of halo, NH2, cyano, haloalkyl, alkyl, alkenyl, alkynyl, -alkynyl-alkyl, -O-alkyl, -alkyl-CN, -alkyl-OH, -alkyl-O-alkyl, -alkyl- NH2, -alkyl-N(alkyl)(alkyl), -alkyl-cycloalkyl, NH2, -N(alkyl)(alkyl), -C(=O)-NH2, -C(=O)-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be unsubstituted or substituted with alkyl or -OH, wherein the alkyl may be unsubstituted or substituted with halo.  Claim 2. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 to X4 are each independently C or N,R1 and R2 are each independently hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C1-6alkyl-cycloalkyl, -C1-6alkyl-heterocycloalkyl, -C1-6alkyl-aryl or -C1-6alkyl-heteroaryl, orR1 and R2 are heterocycloalkyl formed by linking R1 and R2 together,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,R4 is hydrogen, halo, cyano, -NH2, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, -O-C1-6alkyl, -N(R4A)(R4B), -N(R4D)C(=O)(R4C), cycloalkyl, heterocycloalkyl, aryl or heteroaryl,wherein R4A to R4D are each independently hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-heteroaryl, heteroaryl, aryl or -aryl-C(=O)-heterocycloalkyl,R5 is hydrogen, cyano, -C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,R6 is absent, or is hydrogen, cyano, -C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted with one or more selected from the group consisting of halo, NH2, cyano, cycloalkyl, haloalkyl, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C2-6alkynyl-C1-6alkyl, -O-C1-6alkyl, -C1-6alkyl-CN, -C1-6alkyl-OH, -C1-6alkyl-O-C1-6alkyl, -C1-6alkyl-NH2, -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl), -C1-6alkyl-cycloalkyl, -C(=O)-NH2, -C(=O)-heteroaryl, heterocycloalkyl, and heteroaryl, wherein the heterocycloalkyl or heteroaryl may be unsubstituted or substituted with -C1-6alkyl or -OH, wherein the -C1-6alkyl may be unsubstituted or substituted with halo.  Claim 3. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 to X4 are each independently C or N,R1 and R2 are each independently hydrogen or -C1-6alkyl-heterocycloalkyl, wherein the heterocycloalkyl may be unsubstituted or substituted with -C1-6alkyl, orR1 and R2 are 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together,wherein the 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together may be substituted with one or more selected from the group consisting of halo, NH2, cyano, cycloalkyl, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C2-6alkynyl-C1-6alkyl, -C1-6alkyl-CN, -C1-6alkyl-OH, -C1-6alkyl-O-C1-6alkyl, -C1-6alkyl-NH2, -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl), -C1-6alkyl-cycloalkyl, -C(=O)-NH2, -C(=O)-heteroaryl, heterocycloalkyl, and heteroaryl, wherein the heterocycloalkyl or heteroaryl may be unsubstituted or substituted with -C1-6alkyl or -OH, wherein the -C1-6alkyl may be unsubstituted or substituted with halo,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more selected from the group consisting of cyano, -C1-6alkyl, and heterocycloalkyl, wherein the -C1-6alkyl may be unsubstituted or substituted with halo,R4 is hydrogen, halo, -NH2, -C1-6alkyl, -O-C1-6alkyl, -N(R4A)(R4B), or -NHC(=O)(R4C),wherein R4A to R4C are each independently hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-heteroaryl, heteroaryl or -aryl-C(=O)-heterocycloalkyl, wherein the aryl or heteroaryl may be unsubstituted or substituted with halo, -C1-6alkyl, -O-C1-6alkyl, -C1-6alkyl-CN, or -C1-6alkyl-OH,R5 is hydrogen, cyano, or-C1-6alkyl,R6 is absent, or is hydrogen, aryl or heteroaryl.  Claim 4. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 and X4 are each independently C or N,X2 and X3 are N,R1 and R2 are each independently hydrogen or -C1-6alkyl-heterocycloalkyl, wherein the heterocycloalkyl may be unsubstituted or substituted with -C1-6alkyl, orR1 and R2 are 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together, wherein the 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together isor ,wherein R1A to R1S are each independently hydrogen, halo, NH2, cyano, cycloalkyl, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C2-6alkynyl-C1-6alkyl, -C1-6alkyl-CN, -C1-6alkyl-OH, -C1-6alkyl-O-C1-6alkyl, -C1-6alkyl-NH2, -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl), -C1-6alkyl-cycloalkyl, -C(=O)-NH2, -C(=O)-heteroaryl, heterocycloalkyl, or heteroaryl, wherein the heterocycloalkyl or heteroaryl may be unsubstituted or substituted with -C1-6alkyl or -OH, wherein the -C1-6alkyl may be unsubstituted or substituted with halo,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, aryl, or , wherein the aryl may be unsubstituted or substituted with cyano,wherein R3A to R3F are each independently hydrogen, cyano, -C1-6alkyl or heterocycloalkyl, wherein -C1-6alkyl may be unsubstituted or substituted with halo,R4 is hydrogen, halo, -NH2, -C1-6alkyl, -O-C1-6alkyl, -N(R4A)(R4B), or -NHC(=O)(R4C),wherein R4A to R4C are each independently hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-heteroaryl, heteroaryl or -aryl-C(=O)-heterocycloalkyl, wherein the aryl or heteroaryl may be unsubstituted or substituted with halo, -C1-6alkyl, -O-C1-6alkyl, -C1-6alkyl-CN, or -C1-6alkyl-OH,R5 is hydrogen, cyano, or -C1-6alkyl,R6 is absent, or is hydrogen, aryl or heteroaryl.  Claim 5. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 and X4 are each independently C or N,X2 and X3 are N,R1 and R2 are each independently hydrogen or -C1-6alkyl-heterocycloalkyl, wherein the heterocycloalkyl may be unsubstituted or substituted with -C1-6alkyl, orR1 and R2 are 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together, wherein the 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together is or ,wherein R1A and R1B are each independently hydrogen, cyano, or -C1-6alkyl-OH,R1C and R1D are each independently hydrogen, halo, cyano, cycloalkyl, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C2-6alkynyl-C1-6alkyl, -C1-6alkyl-CN, -C1-6alkyl-OH, -C1-6alkyl-O-C1-6alkyl, -C1-6alkyl-NH2, -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl), -C1-6alkyl-cycloalkyl, -C(=O)-NH2, heterocycloalkyl, or heteroaryl, wherein the heterocycloalkyl or heteroaryl may be unsubstituted or substituted with -C1-6alkyl, wherein the -C1-6alkyl may be unsubstituted or substituted with halo,R1E and R1F are each independently hydrogen, halo, cyano, or -C1-6alkyl,R1G and R1H are each independently hydrogen, -C1-6alkyl, -C1-6alkyl-NH2, or -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl),R1I to R1L are each independently hydrogen, halo, NH2 or -C1-6alkyl,R1M is hydrogen, -C(=O)-NH2, or -C(=O)-heteroaryl, wherein the heteroaryl may be unsubstituted or substituted with -OH,R1N to R1S are each independently hydrogen, halo, or -C1-6alkyl,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, aryl, or , wherein the aryl may be unsubstituted or substituted with cyano,wherein R3A to R3C are each independently hydrogen, cyano or -C1-6alkyl,R3D is hydrogen, -C1-6alkyl or heterocycloalkyl, wherein -C1-6alkyl may be unsubstituted or substituted with halo,R3E and R3F are each independently hydrogen or -C1-6alkyl,R4 is hydrogen, halo, -NH2, -C1-6alkyl, -O-C1-6alkyl, -N(R4A)(R4B), or -NHC(=O)(R4C),wherein R4A and R4B are each independently hydrogen, -C1-6alkyl, heteroaryl or -aryl-C(=O)-heterocycloalkyl, wherein the aryl or heteroaryl may be unsubstituted or substituted with halo, -C1-6alkyl, -O-C1-6alkyl, -C1-6alkyl-CN, or -C1-6alkyl-OH,R4C is hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-heteroaryl or heteroaryl, wherein the heteroaryl may be unsubstituted or substituted with -C1-6alkyl,R5 is hydrogen, cyano, or -C1-6alkyl,R6 is absent, or is hydrogen, aryl or heteroaryl.  Claim 6. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 and X4 are each independently C or N,X2 and X3 are N,R1 and R2 are each independently hydrogen or -C1-6alkyl-piperidine, wherein the piperidine may be unsubstituted or substituted with -C1-6alkyl, orR1 and R2 are 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together, wherein the 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together is or ,wherein R1A and R1B are each independently hydrogen, cyano, or -C1-6alkyl-OH,R1C and R1D are each independently hydrogen, halo, cyano, cycloalkyl, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C2-6alkynyl-C1-6alkyl, -C1-6alkyl-CN, -C1-6alkyl-OH, -C1-6alkyl-O-C1-6alkyl, -C1-6alkyl-NH2, -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl), -C1-6alkyl-cycloalkyl, -C(=O)-NH2, piperidine or isoxazole, wherein the piperidine or isoxazole may be unsubstituted or substituted with -C1-6alkyl, wherein the -C1-6alkyl may be unsubstituted or substituted with halo,R1E and R1F are each independently hydrogen, halo, cyano, or -C1-6alkyl,R1G and R1H are each independently hydrogen, -C1-6alkyl, -C1-6alkyl-NH2, or -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl),R1I to R1L are each independently hydrogen, halo, NH2 or -C1-6alkyl,R1M is hydrogen, -C(=O)-NH2, or -C(=O)-pyridine, wherein the pyridine may be unsubstituted or substituted with -OH,R1N to R1S are each independently hydrogen, halo, or -C1-6alkyl,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, aryl, or, wherein the aryl may be unsubstituted or substituted with cyano,wherein R3A to R3C are each independently hydrogen, cyano or -C1-6alkyl,R3D is hydrogen, -C1-6alkyl or morpholine, wherein -C1-6alkyl may be unsubstituted or substituted with halo,R3E and R3F are each independently hydrogen or -C1-6alkyl,R4 is hydrogen, halo, -NH2, -C1-6alkyl, -O-C1-6alkyl, -N(R4A)(R4B), or -NHC(=O)(R4C),wherein R4A and R4B are each independently hydrogen, -C1-6alkyl, pyrazole or -aryl-C(=O)-morpholine, wherein the aryl may be unsubstituted or substituted with -O-C1-6alkyl, wherein the pyrazole may be unsubstituted or substituted with halo, -C1-6alkyl, -C1-6alkyl-CN, or -C1-6alkyl-OH,R4C is hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-pyridine, pyrazole or furan, wherein the pyridine, pyrazole or furan may be unsubstituted or substituted with -C1-6alkyl,R5 is hydrogen or -C1-6alkyl,R6 is absent, or is hydrogen, aryl or heteroaryl. Claim 7. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 and X4 are each independently C or N,X2 and X3 are N,R1 and R2 are each independently hydrogen or -C1-6alkyl-piperidine, wherein the piperidine may be unsubstituted or substituted with -C1-6alkyl, orR1 and R2 are 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together, wherein the 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together is or ,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, aryl, or , wherein the aryl may be unsubstituted or substituted with cyano,wherein R3A to R3C are each independently hydrogen, cyano or -C1-6alkyl,R3D is hydrogen, -C1-6alkyl or morpholine, wherein -C1-6alkyl may be unsubstituted or substituted with halo,R3E and R3F are each independently hydrogen or -C1-6alkyl,R4 is hydrogen, halo, -NH2, -C1-6alkyl, -O-C1-6alkyl, -N(R4A)(R4B), or -NHC(=O)(R4C),wherein R4A and R4B are each independently hydrogen, -C1-6alkyl, pyrazole or -aryl-C(=O)-morpholine, wherein the aryl may be unsubstituted or substituted with -O-C1-6alkyl, the pyrazole may be unsubstituted or substituted with halo, -C1-6alkyl, -C1-6alkyl-CN, or -C1-6alkyl-OH,R4C is hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-pyridine, pyrazole or furan, wherein the pyridine, pyrazole or furan may be unsubstituted or substituted with -C1-6alkyl,R5 is hydrogen or -C1-6alkyl,R6 is absent, or is hydrogen, aryl or heteroaryl.Claim 8. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 and X4 are each independently C or N,X2 and X3 are N,R1 and R2 are each independently hydrogen or -C1-6alkyl-piperidine, wherein the piperidine may be unsubstituted or substituted with -C1-6alkyl,or R1 and R2 are 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together, wherein the 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together is or ,wherein R1A and R1B are each independently hydrogen, cyano, or -C1-6alkyl-OH,R1C and R1D are each independently hydrogen, halo, cyano, cycloalkyl, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C2-6alkynyl-C1-6alkyl, -C1-6alkyl-CN, -C1-6alkyl-OH, -C1-6alkyl-O-C1-6alkyl, -C1-6alkyl-NH2, -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl), -C1-6alkyl-cycloalkyl, -C(=O)-NH2, piperidine or isoxazole, wherein the piperidine or isoxazole may be unsubstituted or substituted with -C1-6alkyl, wherein the -C1-6alkyl may be unsubstituted or substituted with halo,R1E and R1F are each independently hydrogen, halo, cyano, or -C1-6alkyl,R1G and R1H are each independently hydrogen, -C1-6alkyl, -C1-6alkyl-NH2, or -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl),R1I to R1L are each independently hydrogen, halo, NH2 or -C1-6alkyl,R1M is hydrogen, -C(=O)-NH2, or -C(=O)-pyridine, wherein the pyridine may be unsubstituted or substituted with -OH,R1N to R1S are each independently hydrogen, halo, or -C1-6alkyl,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, or , R4 is hydrogen, halo, -NH2, -C1-6alkyl, -O-C1-6alkyl, -N(R4A)(R4B), or -NHC(=O)(R4C),wherein R4A and R4B are each independently hydrogen, -C1-6alkyl, pyrazole or -aryl-C(=O)-morpholine, wherein the aryl may be unsubstituted or substituted with -O-C1-6alkyl, the pyrazole may be unsubstituted or substituted with halo, -C1-6alkyl, -C1-6alkyl-CN, or -C1-6alkyl-OH,R4C is hydrogen, -C1-6alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-pyridine, pyrazole or furan, wherein the pyridine, pyrazole or furan may be unsubstituted or substituted with -C1-6alkyl,R5 is hydrogen or -C1-6alkyl,R6 is absent, or is hydrogen, aryl or heteroaryl. Claim 9. The compound of Formula 1, or a pharmaceutically acceptable salt thereof, according to claim 1,wherein X1 and X4 are each independently C or N,X2 and X3 are N,R1 and R2 are each independently hydrogen or -C1-6alkyl-piperidine, wherein the piperidine may be unsubstituted or substituted with -C1-6alkyl, orR1 and R2 are 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together, wherein the 3- to 10-membered heteromonocycloalkyl or 3- to 10-membered spiro or fused heterobicycloalkyl formed by linking R1 and R2 together is or,wherein R1A and R1B are each independently hydrogen, cyano, or -C1-6alkyl-OH,R1C and R1D are each independently hydrogen, halo, cyano, cycloalkyl, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C2-6alkynyl-C1-6alkyl, -C1-6alkyl-CN, -C1-6alkyl-OH, -C1-6alkyl-O-C1-6alkyl, -C1-6alkyl-NH2, -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl), -C1-6alkyl-cycloalkyl, -C(=O)-NH2, piperidine or isoxazole, wherein the piperidine or isoxazole may be unsubstituted or substituted with C1-6alkyl, wherein the C1-6alkyl may be unsubstituted or substituted with halo,R1E and R1F are each independently hydrogen, halo, cyano, or -C1-6alkyl,R1G and R1H are each independently hydrogen, -C1-6alkyl, -C1-6alkyl-NH2, or -C1-6alkyl-N(C1-6alkyl)(C1-6alkyl),R1I to R1L are each independently hydrogen, halo, NH2 or -C1-6alkyl,R1M is hydrogen, -C(=O)-NH2, or -C(=O)-pyridine, wherein the pyridine may be unsubstituted or substituted with -OH,R1N to R1S are each independently hydrogen, halo, or -C1-6alkyl,R3 is absent, or is hydrogen, halo, cyano, -C1-6alkyl, -C1-6alkyl-O-C1-6alkyl, aryl, or, wherein the aryl may be unsubstituted or substituted with cyano,wherein R3A to R3C are each independently hydrogen, cyano or -C1-6alkyl,R3D is hydrogen, -C1-6alkyl or morpholine, wherein -C1-6alkyl may be unsubstituted or substituted with halo,R3E and R3F are each independently hydrogen or -C1-6alkyl, R4 is hydrogen, halo, -NH2, -C1-6alkyl, -O-C1-6alkyl or,R5 is hydrogen or -C1-6alkyl,R6 is absent, or is hydrogen, aryl or heteroaryl.  Claim 10. The compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt thereof, according to claim 1: Claim 11. The compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt thereof, according to claim 10:Claim 12. The following compound, or a pharmaceutically acceptable salt thereof, according to claim 10: Claim 13. A method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 1, comprising a step of reacting a compound of Formula 2 below and a compound of Formula 3 below:[Formula 2] [Formula 3]wherein are each independently absent or a single bond,X1 to X4 are each independently C or N,Y is halogen,R1 and R2 are each independently hydrogen, alkyl, -O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl, orR1 and R2 are heterocycloalkyl formed by linking R1 and R2 together,R3 is absent, or is hydrogen, halo, cyano, alkyl, -alkyl-O-alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,R4 is hydrogen, halo, cyano, -NH2, -alkyl, -alkyl-O-alkyl, -O-alkyl, -N(R4A)(R4B), -N(R4D)C(=O)(R4C), cycloalkyl, heterocycloalkyl, aryl or heteroaryl,wherein R4A to R4D are each independently hydrogen, alkyl, cycloalkyl, heterocycloalkyl, -cycloalkyl-heteroaryl, heteroaryl, aryl or -aryl-C(=O)-heterocycloalkyl,R5 is hydrogen, cyano, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,R6 is absent, or is hydrogen, cyano, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl,wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted with one or more selected from the group consisting of halo, NH2, cyano, haloalkyl, alkyl, alkenyl, alkynyl, -alkynyl-alkyl, -O-alkyl, -alkyl-CN, -alkyl-OH, -alkyl-O-alkyl, -alkyl-NH2, -alkyl-N(alkyl)(alkyl), -alkyl-cycloalkyl, NH2, -N(alkyl)(alkyl), -C(=O)-NH2, -C(=O)-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be unsubstituted or substituted with alkyl or -OH, wherein the alkyl may be unsubstituted or substituted with halo.Claim 14. A pharmaceutical composition for preventing or treating a disease mediated by or associated with LRRK2, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1.Claim 15. The pharmaceutical composition according to claim 14, wherein the disease mediated by or associated with LRRK2 is Parkinson's disease.  

Images